Earnings summaries and quarterly performance for PROCEPT BioRobotics.
Executive leadership at PROCEPT BioRobotics.
Board of directors at PROCEPT BioRobotics.
Research analysts who have asked questions during PROCEPT BioRobotics earnings calls.
Brandon Vazquez
William Blair & Company, L.L.C.
4 questions for PRCT
Also covers: ALGN, CBLL, CVRX +16 more
Joshua Jennings
TD Cowen
4 questions for PRCT
Also covers: ABT, ALUR, ATEC +20 more
Matthew O'Brien
Piper Sandler & Co.
4 questions for PRCT
Also covers: APYX, ATEC, ATRC +18 more
Richard Newitter
Truist Securities
4 questions for PRCT
Also covers: AXNX, DXCM, GKOS +18 more
Christopher Pasquale
Nephron Research
3 questions for PRCT
Also covers: ALC, AXGN, BSX +12 more
Craig Bijou
Bank of America Securities
3 questions for PRCT
Also covers: BLCO, COO, FNA +9 more
Nathan Treybeck
Wells Fargo Securities
3 questions for PRCT
Also covers: IRTC, ITGR, LMAT +1 more
Patrick Wood
Morgan Stanley
3 questions for PRCT
Also covers: ALC, BDX, BLCO +17 more
Ryan Zimmerman
BTIG
3 questions for PRCT
Also covers: ALC, GEHC, GKOS +23 more
Michael Kratky
Leerink Partners
2 questions for PRCT
Also covers: AXGN, BBNX, DXCM +6 more
Michael Sarcone
Jefferies
2 questions for PRCT
Also covers: ALC, AXGN, CTSO +11 more
Mike Kratky
Leerink Partners
2 questions for PRCT
Also covers: AXGN, DXCM, INSP +4 more
Chris Pasquale
Nephron Research LLC
1 question for PRCT
Also covers: ALC, AXGN, BSX +7 more
Mason Carrico
Stephens Inc.
1 question for PRCT
Also covers: AKYA, CDNA, CSTL +13 more
Suraj Kalia
Oppenheimer & Co. Inc.
1 question for PRCT
Also covers: ABT, AORT, ATRC +14 more
Recent press releases and 8-K filings for PRCT.
PROCEPT Addresses Q3 Utilization and Outlines Future Growth Strategies
PRCT
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- PROCEPT clarified that Q3 utilization was not a procedure problem but rather an inventory workdown situation, with the company focusing on procedure growth over HP sales as a proxy for procedures.
- The company is implementing a more mature launch process for new systems, including requiring screened cases and dedicated launch teams, to drive better utilization and inventory management.
- 2026 is anticipated to be a significant year for the replacement of older AquaBeam systems with the new HYDROS system, as the company develops a cohesive replacement strategy.
- Despite a decrease in the Category I physician fee, hospital facility payments for aquablation increased by 5% year-over-year, remaining very favorable and not expected to be a headwind to business adoption.
- The CEO expressed confidence in the next year's guidance, noting opportunities to exceed it through improved commercial execution, more efficient launches, and an accelerated replacement strategy.
Dec 2, 2025, 1:30 PM
PROCEPT BioRobotics Discusses Q3 Utilization, Capital Sales, and Future Strategy at Healthcare Conference
PRCT
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- PROCEPT BioRobotics is shifting its focus from HP sales to procedure volumes as a key indicator of business health, noting that Q3 utilization commentary reflected an inventory workdown rather than a procedure problem, with management pleased with current procedure growth.
- The company reported strong capital sales in Q3, attributing it to the value proposition and execution, despite increased scrutiny and longer closing times for some deals.
- Management anticipates that 2026 will be a significant year for the replacement cycle of older AquaBeam systems (with a useful life of approximately five years) with the new HYDROS system, which is the focus of all future R&D and innovation.
- PROCEPT's CEO, Larry Wood, discussed initiatives to improve commercial execution, including a dedicated launch team and a new strategy for launching instruments, aiming to drive better utilization and procedure growth to potentially reach the high end of next year's guidance.
- Reimbursement for the facility payment to hospitals increased 5% year-over-year, now two times that of TURP or GreenLight, while a decrease in the Category I physician fee is not expected to be a headwind.
Dec 2, 2025, 1:30 PM
PRCT Reports Strong Q3 2025 Revenue and Provides Preliminary 2026 Guidance
PRCT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- PROCEPT (PRCT) reported Q3 2025 total revenue of $83.3 million, representing 43% growth compared to Q3 2024, primarily driven by U.S. capital system sales totaling $58 million.
- The company maintained its full-year 2025 total revenue guidance of $325.5 million and an Adjusted EBITDA loss of $35 million, but adjusted Q4 handpiece sales guidance downwards due to field inventory optimization.
- For fiscal 2026, PROCEPT anticipates total revenue in the range of $410-$430 million, reflecting current momentum in capital sales and expected modest procedural headwinds in the first half.
- Management is implementing organizational changes and initiatives to improve procedure utilization and the speed of new account launches, while also increasing investment in international markets.
Nov 4, 2025, 9:30 PM
PROCEPT BioRobotics Reports Strong Q3 2025 Results and Issues 2026 Revenue Guidance
PRCT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- PROCEPT BioRobotics reported total revenue of $83.3 million for the third quarter of 2025, an increase of 43% compared to the prior year period.
- The U.S. install base grew by 58 robotic systems in Q3 2025, bringing the total to 653 systems as of September 30, 2025.
- Gross margin for Q3 2025 improved to 65% (from 63% in Q3 2024), and Adjusted EBITDA loss narrowed to $7.4 million (from $12.4 million in Q3 2024).
- The company maintained its fiscal year 2025 total revenue guidance at approximately $325.5 million, representing 45% growth over the prior year.
- Fiscal year 2026 total revenue guidance was issued in the range of $410 million to $430 million, indicating 26% to 32% growth over the 2025 guidance.
Nov 4, 2025, 9:09 PM
PROCEPT BioRobotics Reports Q3 2025 Financial Results and Issues 2026 Revenue Guidance
PRCT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- PROCEPT BioRobotics reported total revenue of $83.3 million for the third quarter of 2025, an increase of 43% compared to the prior year period.
- The company reiterated its fiscal year 2025 total revenue guidance of approximately $325.5 million and issued fiscal year 2026 total revenue guidance in the range of $410 million to $430 million.
- For the third quarter of 2025, the gross margin was 65%, the net loss was $21.4 million, and the Adjusted EBITDA loss was $7.4 million.
Nov 4, 2025, 9:03 PM
Quarterly earnings call transcripts for PROCEPT BioRobotics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more